224 related articles for article (PubMed ID: 30084839)
1. Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression.
Li X; Shepard HM; Cowell JA; Zhao C; Osgood RJ; Rosengren S; Blouw B; Garrovillo SA; Pagel MD; Whatcott CJ; Han H; Von Hoff DD; Taverna DM; LaBarre MJ; Maneval DC; Thompson CB
Clin Cancer Res; 2018 Oct; 24(19):4798-4807. PubMed ID: 30084839
[No Abstract] [Full Text] [Related]
2. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models.
Thompson CB; Shepard HM; O'Connor PM; Kadhim S; Jiang P; Osgood RJ; Bookbinder LH; Li X; Sugarman BJ; Connor RJ; Nadjsombati S; Frost GI
Mol Cancer Ther; 2010 Nov; 9(11):3052-64. PubMed ID: 20978165
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy.
Singha NC; Nekoroski T; Zhao C; Symons R; Jiang P; Frost GI; Huang Z; Shepard HM
Mol Cancer Ther; 2015 Feb; 14(2):523-32. PubMed ID: 25512619
[TBL] [Abstract][Full Text] [Related]
4. PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study.
Seki T; Saida Y; Kishimoto S; Lee J; Otowa Y; Yamamoto K; Chandramouli GV; Devasahayam N; Mitchell JB; Krishna MC; Brender JR
Neoplasia; 2022 Aug; 30():100793. PubMed ID: 35523073
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment.
Kultti A; Zhao C; Singha NC; Zimmerman S; Osgood RJ; Symons R; Jiang P; Li X; Thompson CB; Infante JR; Jacobetz MA; Tuveson DA; Frost GI; Shepard HM; Huang Z
Biomed Res Int; 2014; 2014():817613. PubMed ID: 25147816
[TBL] [Abstract][Full Text] [Related]
6. PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.
Morosi L; Meroni M; Ubezio P; Fuso Nerini I; Minoli L; Porcu L; Panini N; Colombo M; Blouw B; Kang DW; Davoli E; Zucchetti M; D'Incalci M; Frapolli R
J Exp Clin Cancer Res; 2021 Sep; 40(1):286. PubMed ID: 34507591
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).
Wong KM; Horton KJ; Coveler AL; Hingorani SR; Harris WP
Curr Oncol Rep; 2017 Jul; 19(7):47. PubMed ID: 28589527
[TBL] [Abstract][Full Text] [Related]
8. Effective targeting of the tumor microenvironment for cancer therapy.
Jiang P; Li X; Thompson CB; Huang Z; Araiza F; Osgood R; Wei G; Feldmann M; Frost GI; Shepard HM
Anticancer Res; 2012 Apr; 32(4):1203-12. PubMed ID: 22493350
[TBL] [Abstract][Full Text] [Related]
9. Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer Therapy.
Shepard HM
Front Oncol; 2015; 5():192. PubMed ID: 26380222
[TBL] [Abstract][Full Text] [Related]
10. Sugars in the microenvironment: the sticky problem of HA turnover in tumors.
Schmaus A; Bauer J; Sleeman JP
Cancer Metastasis Rev; 2014 Dec; 33(4):1059-79. PubMed ID: 25324146
[TBL] [Abstract][Full Text] [Related]
11. Cancer cell migration in collagen-hyaluronan composite extracellular matrices.
Unnikandam Veettil SR; Hwang D; Correia J; Bartlett MD; Schneider IC
Acta Biomater; 2021 Aug; 130():183-198. PubMed ID: 34116226
[TBL] [Abstract][Full Text] [Related]
12. Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration.
Brundel DH; Feeney OM; Nowell CJ; Suys EJ; Gracia G; Kaminskas LM; McIntosh MM; Kang DW; Porter CJ
Nanomedicine (Lond); 2021 Feb; 16(4):275-292. PubMed ID: 33560142
[No Abstract] [Full Text] [Related]
13. Hyaluronan accumulates with high-fat feeding and contributes to insulin resistance.
Kang L; Lantier L; Kennedy A; Bonner JS; Mayes WH; Bracy DP; Bookbinder LH; Hasty AH; Thompson CB; Wasserman DH
Diabetes; 2013 Jun; 62(6):1888-96. PubMed ID: 23349492
[TBL] [Abstract][Full Text] [Related]
14. Overcoming the stromal barrier for targeted delivery of HPMA copolymers to pancreatic tumors.
Buckway B; Wang Y; Ray A; Ghandehari H
Int J Pharm; 2013 Nov; 456(1):202-11. PubMed ID: 23933441
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronan-Derived Swelling of Solid Tumors, the Contribution of Collagen and Cancer Cells, and Implications for Cancer Therapy.
Voutouri C; Polydorou C; Papageorgis P; Gkretsi V; Stylianopoulos T
Neoplasia; 2016 Dec; 18(12):732-741. PubMed ID: 27886639
[TBL] [Abstract][Full Text] [Related]
16. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer.
Karousou E; Misra S; Ghatak S; Dobra K; Götte M; Vigetti D; Passi A; Karamanos NK; Skandalis SS
Matrix Biol; 2017 May; 59():3-22. PubMed ID: 27746219
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-induced alterations in hyaluronan and hyaluronidase.
Gao F; Okunieff P; Han Z; Ding I; Wang L; Liu W; Zhang J; Yang S; Chen J; Underhill CB; Kim S; Zhang L
Adv Exp Med Biol; 2005; 566():249-56. PubMed ID: 16594159
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
Infante JR; Korn RL; Rosen LS; LoRusso P; Dychter SS; Zhu J; Maneval DC; Jiang P; Shepard HM; Frost G; Von Hoff DD; Borad MJ; Ramanathan RK
Br J Cancer; 2018 Jan; 118(2):153-161. PubMed ID: 28949957
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronan metabolism: a major paradox in cancer biology.
Stern R
Pathol Biol (Paris); 2005 Sep; 53(7):372-82. PubMed ID: 16085113
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials.
Arias-Lorza AM; Costello JR; Hingorani SR; Von Hoff DD; Korn RL; Raghunand N
Sci Rep; 2024 May; 14(1):11570. PubMed ID: 38773189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
